HighVista Strategies LLC Has $3.11 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

HighVista Strategies LLC decreased its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 33.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,942 shares of the company’s stock after selling 40,461 shares during the period. Apogee Therapeutics accounts for 1.1% of HighVista Strategies LLC’s investment portfolio, making the stock its 18th biggest holding. HighVista Strategies LLC owned approximately 0.14% of Apogee Therapeutics worth $3,106,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Darwin Global Management Ltd. bought a new position in shares of Apogee Therapeutics during the 1st quarter worth about $55,300,000. Vanguard Group Inc. boosted its stake in Apogee Therapeutics by 60.7% in the first quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock worth $124,173,000 after purchasing an additional 705,795 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Apogee Therapeutics by 51.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,170,327 shares of the company’s stock worth $77,770,000 after purchasing an additional 399,646 shares during the last quarter. Farallon Capital Management LLC acquired a new stake in shares of Apogee Therapeutics in the first quarter valued at $20,267,000. Finally, Jennison Associates LLC raised its stake in shares of Apogee Therapeutics by 192.0% in the first quarter. Jennison Associates LLC now owns 302,892 shares of the company’s stock worth $20,127,000 after acquiring an additional 199,148 shares during the last quarter. 79.04% of the stock is currently owned by institutional investors.

Apogee Therapeutics Price Performance

APGE opened at $58.43 on Monday. The stock has a market capitalization of $3.42 billion, a P/E ratio of -11.13 and a beta of 2.74. The company’s 50 day simple moving average is $47.99 and its 200-day simple moving average is $49.89. Apogee Therapeutics, Inc. has a one year low of $14.19 and a one year high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last released its earnings results on Monday, August 12th. The company reported ($0.60) EPS for the quarter, meeting the consensus estimate of ($0.60). As a group, analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 EPS for the current year.

Insider Buying and Selling

In other news, insider Carl Dambkowski sold 5,995 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total transaction of $225,412.00. Following the completion of the transaction, the insider now directly owns 294,793 shares in the company, valued at approximately $11,084,216.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $47.62, for a total transaction of $1,904,800.00. Following the transaction, the chief executive officer now directly owns 1,394,487 shares of the company’s stock, valued at $66,405,470.94. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Carl Dambkowski sold 5,995 shares of the company’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total transaction of $225,412.00. Following the completion of the sale, the insider now owns 294,793 shares of the company’s stock, valued at approximately $11,084,216.80. The disclosure for this sale can be found here. Insiders sold a total of 120,995 shares of company stock valued at $5,218,774 over the last three months. Company insiders own 36.10% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.